Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00877747|
Recruitment Status : Unknown
Verified October 2015 by DR. ANDREA GALLAMINI, Ospedale Santa Croce-Carle Cuneo.
Recruitment status was: Active, not recruiting
First Posted : April 8, 2009
Last Update Posted : October 19, 2015
Early interim-PET after two courses of chemotherapy is a powerful outcome predictor in advanced-stage Hodgkin Lymphoma (HL) patients treated with adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD). Two-year Progression Free Survival of PET-2 positive patients is only 12%, but the optimal treatment for this patient subset is still unknown.
From January 2006 GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) suggested an early intensification of chemotherapy with BEACOPP [Bleomycin, Etoposide, Adriamycin (doxorubicin), Cyclophosphamide, Oncovin (vincristine), Procarbazine, and Prednisone](4 escalated + 4 baseline cycles) for all the HL patients with a positive PET-2 after 2 ABVD courses. The investigators retrospectively recorded and analyzed these data in order to evaluate if this strategy could be of benefit for this subset of patients.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||160 participants|
|Official Title:||Early Chemotherapy Intensification With BEACOPP in High-risk, Interim-PET Positive Advanced-stage Hodgkin Lymphoma:a GITIL Retrospective Multicenter Clinical Study|
|Study Start Date :||January 2006|
|Primary Completion Date :||November 2014|
|Estimated Study Completion Date :||October 2015|
Patients with negative early interim PET after 2 courses of ABVD who continued therapy with ABVD
Patients with positive early interim PET after 2 courses of ABVD who changed their therapy to BEACOPP
- Progression Free Survival [ Time Frame: 2 years ]
- Incidence of progression/relapse [ Time Frame: 2 years ]
- Interim PET positive and negative predictive value [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00877747
|Azienda Ospedaliera Santa Croce e Carle|
|Cuneo, Italy, 12100|
|Principal Investigator:||Andrea Gallamini, MD||Azienda Ospedaliera Santa Croce e Carle|